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Abstract
Background: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the most potent congener of the dioxin class of
environmental contaminants. Exposure to TCDD causes a wide range of toxic outcomes, ranging from chloracne
to acute lethality. The severity of toxicity is highly dependent on the aryl hydrocarbon receptor (AHR). Binding
of TCDD to the AHR leads to changes in transcription of numerous genes. Studies evaluating the transcriptional
changes brought on by TCDD may provide valuable insight into the role of the AHR in human health and
disease. We therefore compiled a collection of transcriptomic datasets that can be used to aid the scientific
community in better understanding the transcriptional effects of ligand-activated AHR.
Results: Specifically, we have created a datasets package – TCDD.Transcriptomics – for the R statistical environment,
consisting of 63 unique experiments comprising 377 samples, including various combinations of 3 species (human
derived cell lines, mouse and rat), 4 tissue types (liver, kidney, white adipose tissue and hypothalamus) and a wide
range of TCDD exposure times and doses. These datasets have been fully standardized using consistent preprocessing
and annotation packages (available as of September 14, 2015). To demonstrate the utility of this R package, a subset of
“AHR-core” genes were evaluated across the included datasets. Ahrr, Nqo1 and members of the Cyp family were
significantly induced following exposure to TCDD across the studies as expected while Aldh3a1 was induced
specifically in rat liver. Inmt was altered only in liver tissue and primarily by rat-AHR.
Conclusions: Analysis of the “AHR-core” genes demonstrates a continued need for studies surrounding the impact
of AHR-activity on the transcriptome; genes believed to be consistently regulated by ligand-activated AHR show
surprisingly little overlap across species and tissues. Until now, a comprehensive assessment of the transcriptome
across these studies was challenging due to differences in array platforms, processing methods and annotation
versions. We believe that this package, which is freely available for download (http://labs.oicr.on.ca/boutros-lab/tcdd-
transcriptomics) will prove to be a highly beneficial resource to the scientific community evaluating the effects of
TCDD exposure as well as the variety of functions of the AHR.
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Background
The aryl hydrocarbon receptor (AHR) is an evolutionar-
ily conserved transcription factor [1] activated by small
molecule binding. Prior to ligand-activation, the AHR
resides in the cytoplasm bound to chaperone proteins,
including heat shock protein 90 (HSP90) and the AHR-
interacting protein (AIP) [2, 3]. Ligand-activation of this
receptor leads to translocation into the nucleus, dissoci-
ation of chaperones and dimerization with the AHR
nuclear translocator (ARNT) [4]. The AHR: ARNT com-
plex is able to bind DNA at recognized motifs known as
aryl hydrocarbon response elements (AHREs) whereby
transcription of the associated genes is regulated [5].
Modulation of AHR activity has been linked to various
diseases, including numerous in vitro studies of breast
[6–8], endometrial [9], kidney [10], lung [11, 12] and
prostate [13] cancers and inflammatory skin [14] and
bowel [15, 16] diseases.
Activation of the AHR can occur by both endogenous
molecules, such as tryptophan metabolites [17], and
exogenous molecules, such as polycyclic aromatic hydro-
carbons. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is
the most potent congener of chlorinated dioxins, a large
class of environmental contaminants produced as a by-
product of various industrial processes [18]. Many of the
toxic effects of TCDD exposure, including chloracne,
immunosuppression, hepatotoxicity and cancer [19], are
mediated by the AHR. Strong evidence for this relation-
ship comes from studies of AHR-knockout mice [20–22],
mice containing AHR-inactivating mutations [23–25] and
conditional ARNT-null mice [26], all of which are unre-
sponsive, or show reduced response, to TCDD. Differ-
ences in the toxic outcomes of TCDD occur across
species and have been linked to polymorphisms in the
AHR. A particularly TCDD-resistant strain of mice, DBA/
2 J, presents with an Ala375Val mutation within the AHR
gene; this leads to reduced affinity of the receptor for
TCDD [27–29]. As another example, two strains of rat,
Long-Evans (L-E) and Han/Wistar (H/W) show dramatic
differences in TCDD susceptibility. These differences are
primarily due to a point mutation that results in partial
deletion of the transactivation domain of the AHR in the
TCDD-resistant H/W rat [30]. Furthermore, inbred lines
(Line A/B/C) derived from L-E x H/W crosses demon-
strate intermediate susceptibility to TCDD depending on
AHR genotype [31]. In humans, the AHR gene most
closely resembles that of the DBA/2 J mouse [29]. How-
ever, a number of polymorphisms have been identified
within both the ligand-binding and transactivation do-
mains of the human AHR [32] but the overall functional
consequences of these polymorphisms are not yet clear.
In addition to the differences in TCDD-response phe-
notypes among different mammals, TCDD exposure
results in tissue-specific responses. In rats, TCDD tends
to accumulate in liver, spleen, adipose tissue and pancreas
[33]. The broadest spectrum of transcriptional responses
in rodents is detected in liver [34]. Further compounding
the issue, there is a sex-dependent element to the tran-
scriptomic alterations evoked by TCDD [35–38].
Despite considerable study into the transcriptomic
changes mediated by the TCDD: AHR complex that lead
to the observed toxic outcomes, the specific genes and
pathways responsible for these outcomes remain un-
known. As such, a global resource describing transcrip-
tomic changes following activation of the AHR across a
wide variety of tissues and species would prove very
useful to the scientific community. Therefore, we have
generated such a resource consisting of transcriptomic
data from numerous studies in our laboratory and others
(a total of 377 samples) and we introduce the freely-
available TCDD.Transcriptomics package for the R
statistical environment.
Implementation
Experimental methods
The experimental design, animal handling and sample
preparation for individual experiments are described
elsewhere [34, 37–43]. Data from human Multipotent
Adipose-Derived Stem (hMADS) cells (differentiated
and undifferentiated; TCDD treated and control) were
downloaded from NCBI’s GEO repository (GSE32026)
[42], as were data for primary human and female Spra-
gue–Dawley (SD) rat hepatocyte cell lines (GSE14555)
[44]. Array data for DBA/2 J mouse liver were generated
in our laboratories as follows: briefly, adult male DBA/
2 J mice were bred in the colonies of the National Public
Health Institute, Division of Environmental Health,
Kuopio, Finland. Study plans were approved by the
Finnish National Animal Experiment Board (Eläinkoe-
lautakunta, ELLA; permit code: ESLH-2008-07223/Ym-
23). Animals were housed singly in Makrolon cages with
aspen chip bedding (Tapvei Oy, Kaavi, Finland) and
provided with Altromin 1314 pellet feed (Altromin
Spezialfutter GmbH & Co. KG, Lage, Germany) and
water available ad libitum. The housing environment
was maintained at 21 ± 1 °C, with a relative humidity of
50 ± 10% and a 12 h light cycle. TCDD (5 or 500 μg/kg
dissolved in corn oil) or corn oil vehicle alone were
administered by oral gavage (10 mL/kg). Animals were
euthanized by carbon dioxide, followed immediately by
cardiac exsanguination 19 h following treatment. Livers
were excised and frozen in liquid nitrogen. Tissue sam-
ples were shipped on dry ice to the analytic laboratory
and stored at −80 °C.
Similarly, adult male transgenic “AHR-ratonized” mice,
ages 12–23 weeks, were bred as above. Mice were housed
singly in suspended, wire-mesh stainless-steel or Makrolon
cages, with the housing environment maintained as
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described above. Animals were provided with R36 pellet
feed (Lactamin, Stockholm, Sweden) and tap water avail-
able ad libitum. Animals (n = 83) were divided into 5
groups per Ahr isoform (INS/DEL/rWT) and TCDD
(125, 250, 500, or 1000 μg/kg dissolved in corn oil) or
corn oil vehicle alone were administered by oral gavage
(10 mL/kg). Animals were euthanized by cervical
dislocation 4 days following exposure. Tissue was
collected and stored as above.
Animal handling and reporting comply with ARRIVE
guidelines [45]. RNA isolation and microarray hybridization
were performed as described elsewhere [37, 38, 46].
Remaining data were generated and deposited in the
GEO repository as described in the original publica-
tions [34, 37–41, 43].
Computational methods
Human cell lines
For hMADS cells, raw GenePix image data (.gpr files)
were loaded into the R statistical environment (v3.2.1)
using the limma (v3.24.13) package. Efforts were made
to emulate the processing procedures conducted by the
original authors: images were first cleaned by filtering
out bad spots (flagged as “bad”, “not found” or “absent”
or known as −100, −50 and −75 respectively) by assign-
ing those spots a weight of zero. Normalization was per-
formed within arrays by applying global LOESS. Agilent
Feature IDs were annotated with EntrezGene IDs and
gene names using an annotation table obtained from
NCBI's GEO repository for the array type (GPL4133).
Linear modelling was conducted to identify genes with
statistically significant differential mRNA abundances
between TCDD-treated and reference samples. An em-
pirical Bayes method was applied following model fitting
to reduce standard error and moderated t-tests were
used to assess statistical significance [47]. All p-values
were adjusted for multiple testing using a 5% false
discovery rate (FDR) [48]. Genes with multiple mapped
Agilent Feature IDs were trimmed by keeping the
feature ID with the lowest p-value.
For primary human hepatocyte cell line data, CEL files
were downloaded from GEO (GSE14555) and loaded
into the R statistical environment (v3.3.1) using the affy
package (v1.48.0) of the BioConductor library [49]. Due
to limited sample size, data for both sexes and all dose
points were processed together. Data were normalized
using the RMA algorithm [50] and probe annotations
were obtained using the custom CDF [51] hgu133ahsen-
trezgcdf (v19.0.0) and database hgu133ahsentrezg_db
(v19.0.0) packages. Probes were filtered using a back-
ground intensity threshold established by evaluating
chromosome Y associated probes in female samples. Lin-
ear modelling was performed using the limma (v3.28.21)
package, with contrasts fit to identify differences
between treatment and control groups for each treat-
ment dose. An empirical Bayes moderation of the stand-
ard error [47] was applied, and model-based t-tests were
used to assess significance, accompanied by FDR correc-
tion for multiple testing [48].
Mouse data
Raw CEL files for livers from male and female C57BL/6
mice treated with TCDD or corn oil along a time-course
(GSE61037) were loaded in the R statistical environment
(v3.2.1) using the affy package (v1.46.1)as described
above. Data for both sexes and all time points were pre-
processed together and normalized using the RMA algo-
rithm [50]. Probe annotations were obtained using the
custom CDF [51] mogene11stmmentrezgcdf (v19.0.0)
and database mogene11stmmentrezg_db (v19.0.0) pack-
ages. Chromosome Y probe filtering was performed as
described above. Linear modelling was performed separ-
ately for each time point with both male and female
samples using the limma (v3.24.13) package. An empir-
ical Bayes moderation of the standard error [47] was
applied, and model-based t-tests were used to assess
significance, accompanied by FDR correction for mul-
tiple testing [48].
Data from the corresponding dose–response study
were processed similarly with the following exceptions:
male and female samples were preprocessed and mod-
elled separately to avoid masking sex-specific effects at
low dose treatments. As such, no additional probe filter-
ing was performed. Similarly, transgenic “AHR-rato-
nized” mouse data were preprocessed and modelled
independently for each AHR genotype with no add-
itional probe filtering. Dose–response data from DBA/
2 J mouse liver were processed and modelled as a single
dataset using the above methods.
Rat data
For each experiment, raw CEL files were loaded in the R
statistical environment (v3.2.1) using the affy package
(v1.46.1) of the BioConductor library [49]. Rat adipose
data (GSE18301) were preprocessed as a whole, includ-
ing both strains and time points, using the RMA
algorithm [50] with the custom rat2302rnentrezgcdf
(v19.0.0) package [51]. Probes were further annotated
with gene symbols and named using the rat2302rnen-
trezg_db (v19.0.0) package. Linear modelling was per-
formed on all samples using the limma (v3.24.13)
package, with contrasts fit to specify individual compari-
sons for both strains. Experiments at the day-1 time-
point evaluated TCDD relative to corn oil, whereas the
4-day experiment compared TCDD with feed-restricted,
corn oil treated controls. As above, an empirical Bayes
moderation of the standard error [47] was applied, and
model-based t-tests were used to assess significance,
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accompanied by FDR correction for multiple testing
[48]. Identical processing was performed for data gener-
ated from rat hypothalamus at 23 h (GSE61039) and rat
liver at 4 and 10 day time points (GSE13513). Data from
rat liver, 3 and 19 h time points (GSE10083), were proc-
essed together as described above using the custom
rae230arnentrezgcdf (v19.0.0) package [51].
CEL files for the primary rat hepatocyte cell line data-
set were downloaded from GEO (GSE14555) and loaded
into the R statistical environment (v3.3.1) using the affy
package (v1.48.0) of the BioConductor library [49]. Data
were normalized using the RMA algorithm [50] and
probe annotations were obtained using the custom CDF
[51] rgu34arnentrezgcdf (v19.0.0) and database rgu34ar-
nentrezg_db (v19.0.0) packages. As this specifc array
type does not include probes for genes located on
chromosome Y, no additional filtering was performed.
Linear modelling was performed using the limma
(v3.28.21) package, with contrasts fit to identify differ-
ences between treatment and control groups for each
treatment dose. An empirical Bayes moderation of the
standard error [47] was applied, and model-based t-tests
were used to assess significance, accompanied by FDR
correction for multiple testing [48].
Interspecies comparisons
All interspecies comparisons may be facilitated using
homologene IDs provided by NCBI. A function is pro-
vided in the TCDD.Transcriptomics package to load
filtered HomoloGene data (build 68) for comparison of
mouse, rat and human transcriptomic responses to
TCDD.
Package access
The TCDD.Transcriptomics package is available for
download from http://labs.oicr.on.ca/boutros-lab/tcdd-
transcriptomics, along with instructions for direct
download and installation within the R statistical environ-
ment. TCDD.Transcriptomics is designed for use with the
R statistical environment (≥ v2.10.1) and is dependent on
Table 1 Summary of TCDD Datasets
Species Tissue Strain/AHR
Genotype
Sex Number of Samples Dose(s) (μg/kg) Time(s) (hours) GEO Accession
Human adipose-derived stem
cells
hWT N/A 8 25nM 48 GSE32026
primary hepatocyte
cell line
hWT male and female 3 0.00001, 0.001, 0.01,
0.1, 1, 10, 316 (nM)
48 GSE14555
Mouse kidney C57BL/6 male 12 0, 1000 19 GSE15857
AHR-KO male 6
liver C57BL/6 male 62 0, 125, 250, 500, 1000 6, 19, 24, 72, 96, 144 GSE15858
GSE61037
GSE61038
female 47 6, 24, 72, 96, 144 GSE61037
GSE61038
DBA/2 male 12 0, 5, 500 19 NA
AHR-KO male 6 0, 1000 19 GSE15858
rWT (L-E) male 17 0, 125, 250, 500, 1000 96 GSE72270
DEL (H/W) male 21
INS (H/W) male 22
Rat adipose L-E male 20 0, 100 24, 96 GSE18301
H/W male 8 24
hypothalamus L-E male 7 23 GSE61039
H/W male 8
liver L-E male 39 3, 19, 96, 240 GSE10083
GSE13513
H/W male 30
Ln-A (H/W) male 8 19 GSE10083
Ln-C (L-E) male 8
primary hepatocyte
cell line
rWT (SD) female 14 0.00001, 0.001, 0.01,
0.1, 1, 10, 316 (nM)
48 GSE14555
A total of 63 datasets are included in this package consisting of 377 samples across 3 species, 4 tissue types and a wide range of AHR genotypes, TCDD exposure
times and doses
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the BoutrosLab.plotting.general (BPG) package (≥ v3.10.2)
(P’ng et al., submitted) for production of plotting covariates
and easy integration with data visualizations. The BPG
package can be found here: http://labs.oicr.on.ca/boutros-
lab/software/bpg.
Results and Discussion
In recent years, activation of the AHR has become the
focus of myriad studies across a wide range of fields. In
particular, significant effort has gone into elucidating the
mechanism by which TCDD activation of the AHR leads
to a diversity of toxic outcomes. As the ligand-activated
AHR is a transcription factor, the transcriptome has
been the primary focus of these studies. As such, we
have collated a number of transcriptomic datasets aris-
ing from various TCDD exposure studies in rats, mice
and human cell lines (Table 1, Additional file 1) into a
datasets package for the R statistical environment. Spe-
cifically, microarray data from 12 separate studies cover-
ing 63 unique experimental conditions were collected.
Data were generated using two microarray platforms
and seven unique array types: Agilent’s Whole Human
Genome Microarray and Affymetrix’s Human Genome
U133A Array, Rat Expression Array (230A), Rat Genome
U34 and 230 2.0 Arrays, Mouse Genome 430 2.0 Array
and Mouse Gene 1.1 ST Array. Data from Affymetrix ar-
rays were processed using the RMA algorithm with the
most recent probe to EntrezGeneID map (as described in
Materials and Methods), analyzed using linear modelling,
FDR-corrected for multiple testing and results format-
standardized.
Each dataset is labelled with a highly descriptive title, in-
dicating the species, strain, tissue type, length of exposure
(hours), TCDD dose (μg/kg) and sex (male if unlabelled)
from which the data were generated. Furthermore, each
dataset contains three parts: the sample information, pre-
processed data and analysis results. First, the sample infor-
mation file outlines the type and treatment conditions for
each sample in the experiment. The second file contains
the expression data and consists of the normalized array
data for all samples listed in the sample information file.
Finally, the results file outlines the magnitude and signifi-
cance of change as determined by linear modelling for
each gene available on the array. In this file, all genes are
annotated with EntrezGene IDs, gene symbol and full
gene name.
To provide an example of the usefulness of this R pack-
age, a set of widely recognized “AHR-core” genes, genes
with mRNA transcription known to be regulated by the
AHR transcription factor in a wide range of species and tis-
sues [52–57], were visualized across the available datasets
(Fig. 1). Data was extracted according to Homologene ID
in order to ensure the suitability of comparisons across
species. Interestingly, while most of the selected genes
Fig. 1 “AHR-core” genes. Transcriptional response (treatment relative to control) of a subset of 10 “AHR-core” genes across the available datasets
demonstrates unexpected variability. Dot size indicates magnitude of change in mRNA abundance; colour represents direction of change;
background shading demonstrates significance of change. Boxes containing an ‘X’ indicate that data for the given gene was not available for the
indicated dataset
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show some degree of TCDD-mediated change in transcript
levels across the datasets, some genes demonstrate a spe-
cies and/or tissue specific effect. In particular, ALDH3A1
appears to be induced only in rat liver and primary
human hepatocytes. Similarly, INMT is repressed in
livers of rats and TCDD-sensitive “AHR-ratonized”
mice. The variability in response to the “AHR-core”
genes highlights the need for further study into the
effects of TCDD on various organisms.
While the TCDD.Transcriptomics package provides ac-
cess to a wide range of datasets, it is by no means fully
comprehensive. The GEO repository contains a number of
additional datasets relating to array-based mRNA abun-
dance studies of TCDD-mediated transcriptional regula-
tion, however these typically pertain to gestational exposure
in mice and rats, human cancer-derived cell lines and zebra
fish – all of which are beyond the current scope of this
package but may be incorporated at a later date.
Conclusion
Here we have produced a standardized compendium of
TCDD-mediated transcriptional changes for use in the R
statistical environment. This package, titled TCDD.Tran-
scripomics, contains data from 63 experiments including
377 samples, incorporating data from 3 species, 4 tissue
types, both sexes and a wide range of AHR genotypes,
TCDD exposure times and doses, along with an up-to-
date HomoloGene dataset for interspecies comparison,
and is freely available for download (http://labs.oicr.on.ca/
boutros-lab/tcdd-transcriptomics). This datasets package
will provide a significant resource for the scientific com-
munity encompassing a variety of fields of study, from
toxicological studies concerning TCDD and dioxins to
studies of the AHR and its role in normal physiology and
human disease.
Availability and requirements
Project name: TCDD Transcriptomics
Project home page: http://labs.oicr.on.ca/boutros-lab/
tcdd-transcriptomics
Operating system(s): tested on Ubuntu and Debian
Programming language: R
Other requirements: depends on BPG (http://labs.oicr.on.ca/
boutros-lab/software/bpg)
Licence: GPL-2
Additional file
Additional file 1: Overview of Included TCDD Datasets. (XLSX 16 kb)
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